GSK3B and Alzheimer disease: Inhibition of GSK3β not only promotes autophagy but also mitigates the adverse effects of dysregulated autophagic processes, thereby providing a potential therapeutic target for AD (Kerr et al., 2017; Kong et al., 2019).